APA

Antipsychotic plasma levels play a critical role of in treatment decisions. Learn more in this conversation from the 2025 APA Annual Meeting.

Although there are topics in psychiatry that not exciting, Dr Ghaemi sees plenty of opportunities.

Mena Mirhom, MD, the Psychiatric Times Media & Psychiatry Section Editor, discusses media training for psychiatry fellows, enhancing their skills to effectively communicate and combat misinformation.

Poster presented at the APA Annual Meeting finds zuranolone effective for anhedonia associated with PPD.

Dr Nassir Ghaemi explores the long-term effects and safety of serotonin reuptake inhibitors, revealing benefits and potential risks.

Ramaswamy Viswanathan, MD, DrMedSc, emphasizes the vital role of lifestyle in mental health treatment and advocates for holistic approaches to prevent premature death at the 2025 APA Annual Meeting.

A nonprofit aims to support clinicians and patients with insurance coverage for evidence-based medicine.

Badr Ratnakaran, MBBS, highlights the growing loneliness epidemic and emphasizes its severe impact on mental and physical health at the 2025 APA Annual Meeting.

Resilience: how does it improve overall health? Helen Lavretsky, MD, shared her thoughts at the 2025 APA Annual Meeting.

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.

Research from the 2025 APA Annual Meeting reveals a strong link between borderline personality disorder and problematic internet use, highlighting impulsivity and compulsivity in affected individuals.

Attendees at the 2025 APA Annual Meeting are excited to connect with peers and experts, exploring lifestyle medicine and networking opportunities for career growth.

Mental health professionals recognize the profound impact of climate change on anxiety, depression, and overall well-being, urging proactive support for affected patients, says one APA attendee.

Can GLP-1 agonists support patients on antipsychotics? Amir Meftah, MD, and colleagues explore its use.

Angelo Chaia, MD, explores the impact of long-acting injectables on patients with severe mental illness and substance use disorders at the 2025 APA Annual Meeting.

At the APA Annual Meeting, Dana Hilt, MD, PhD, explores the notion of precision psychiatry in depression treatment.

Amir Meftah, MD, discusses the possibility of GLP-1s for addressing metabolic issues associated with antipsychotics.

Dana Hilt, MD, PhD, discusses data on Xanamem’s impact on cortisol and its potential use in MDD at the APA Annual Meeting.

What should you know about the lesser known psychedelics? Clinical insights from Jacob Perlson, MD, MPH, at the APA Annual Meeting.

Our board members are presenting at this year's APA Annual Meeting. Be sure to check out their sessions!

An expert shares some clinical pearls from his lecture at the recent American Psychiatric Association Annual Meeting.

Here's everything you need to know about about the 2024 APA Annual Meeting and how to prep for next year's meeting, from members of the Scientific Program Committee.

Here's what you need to do following big conferences like the 2024 APA Annual Meeting.

H. Steven Moffic, MD, received the Abraham Halpern Humanitarian Award at the 2024 American Psychiatric Association Annual Meeting. Here’s what he spoke about during his acceptance.

According to the chief medical officer of MindMed, it is time to look past the history of LSD.

Pharmacogenomics at the 2024 APA Annual Meeting.

Sudhakar K. Shenoy, MD, discusses annual meeting, hot topics in child and adolescent psychiatry, and other issues in psychiatry.

Can you form a human bond virtually?

Biases can be apparent in case notes. Psychiatric Times Editor-in-Chief sat down with us at the 2024 APA Annual Meeting to share more.

Here are highlights from the last day of this year’s APA Annual Meeting.